Ophthalmology · Jacksonville, FL
NPI
1841290657
Since 2005
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
8786 Perimeter Park Blvd
Jacksonville, FL, 32216
Phone (904) 997-9202
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.2M
30,554 services
Medicare patients, 2024
1,390
Average age 77
Drug cost, 2024
$893K
2,369 prescriptions
Company payments, 2025
$222
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James A Staman was code J2777 (injection, faricimab-svoa, 0.1 mg), 10,200 times for 63 patients. In total James A Staman billed 30,554 services in 48 codes, and Medicare paid $4.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-09-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2777 Injection, faricimab-svoa, 0.1 mg | Office | 10,200 | 63 | $26.61 | $271K |
| J0177 Injection, aflibercept hd, 1 mg | Office | 4,304 | 156 | $259.49 | $1.1M |
| Q5128 Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 4,035 | 165 | $181.72 | $733K |
| 67028 Intravitreal Injection | Office | 2,070 | 403 | $96.17 | $199K |
| 92134 Computerized Ophthalmic Imaging | Office | 1,810 | 571 | $29.81 | $54K |
| 92250 Angiography | Office | 1,631 | 1,263 | $26.06 | $42K |
| J0178 Injection, aflibercept, 1 mg | Office | 1,502 | 188 | $640.77 | $962K |
| 92014 Ophthalmological E&M | Office | 1,255 | 948 | $84.79 | $106K |
| J2782 Injection, avacincaptad pegol, 0.1 mg | Office | 720 | 11 | $86.27 | $62K |
| 99213 Office E&M - Established | Office | 712 | 436 | $66.46 | $47K |
| 92004 Ophthalmological E&M | Office | 368 | 368 | $104.99 | $39K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 364 | 72 | $48.39 | $18K |
| J0179 Injection, brolucizumab-dbll, 1 mg | Office | 312 | 11 | $249.94 | $78K |
| J3490 Unclassified drugs | Office | 139 | 65 | $2,070.31 | $288K |
| 99427 Chronic, Principal, and Transitional Care Management | Office | 83 | 52 | $36.71 | $3,047 |
By year: 2022 $3.7M for 21,969 services; 2023 $3.3M for 32,599 services; 2024 $4.2M for 30,554 services.
Medicare prescription drug claims, 2024
In 2024, the drug James A Staman prescribed most often to Medicare patients was Prednisolone Acetate, with 411 prescriptions and refills. In total James A Staman wrote 2,369 Medicare prescriptions that cost $893K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisolone Acetate Generic | 411 | 661 | 263 | $22K |
| Latanoprost Generic | 366 | 724 | 121 | $3,253 |
| Brimonidine Tartrate Generic | 291 | 593 | 117 | $4,166 |
| Eylea Aflibercept | 185 | 196 | 53 | $462K |
| Ketorolac Tromethamine Generic | 179 | 307 | 71 | $5,207 |
| Dorzolamide Hcl Generic | 159 | 327 | 60 | $2,616 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 125 | 130 | 103 | $1,325 |
| Atropine Sulfate Generic | 114 | 161 | 105 | $3,801 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 72 | 138 | 26 | $1,008 |
| Eylea Hd Aflibercept | 58 | 68 | 18 | $171K |
| Diclofenac Sodium Generic | 47 | 63 | 16 | $439 |
| Erythromycin Erythromycin Base | 40 | 40 | 36 | $347 |
| Timolol Maleate Generic | 40 | 75 | 23 | $521 |
| Vabysmo Faricimab-Svoa | 36 | 51 | 13 | $79K |
| Rhopressa Netarsudil Mesylate | 30 | 39 | Under 11 | $12K |
Brand drugs: 1,005 claims; generic drugs: 1,364 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James A Staman $222 ($222 in general payments such as food, travel and fees) from 3 companies. The largest payer was Harrow Eye, LLC with $154.
| Company | Payments | Amount |
|---|---|---|
| Harrow Eye, LLC | 1 | $154 |
| Lumibird Medical Inc. | 1 | $42.3 |
| Carl Zeiss Meditec USA, Inc. | 1 | $25.56 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.